November 11, 2025 a 09:00 pm
DHR: Analysts Ratings - Danaher Corporation
Danaher Corporation continues to maintain a strong market presence with diverse segments in Life Sciences, Diagnostics, and Environmental & Applied Solutions. Recent analyst ratings suggest a predominantly positive outlook, with the majority leaning towards Buy or Strong Buy recommendations. The company's strategic positioning in technology and healthcare markets provides it with a competitive edge in innovation-heavy industries.
Historical Stock Grades
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 3 | |
| Buy | 17 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, DHR has experienced a notable shift in analyst ratings. While Strong Buy ratings have slightly decreased, Buy ratings remain consistent, highlighting confidence in continued growth. Hold ratings have increased, suggesting cautious optimism. Total ratings have remained relatively stable, illustrating a steady analyst focus.
- Decrease in Strong Buy ratings since mid-2025.
- Consistent Buy ratings, indicating sustained confidence in the company's performance.
- Increase in Hold ratings, reflecting a more conservative approach by some analysts.
Percentage Trends
A detailed analysis of rating percentages reveals subtle shifts. A slight reduction in Strong Buy percentages highlights increasing caution. However, the high percentage of Buy ratings underscores continued optimism. Hold percentages have risen notably, indicating increased analyst caution amidst a strong buy climate.
- November 2025: 10% Strong Buy, 57% Buy, 10% Hold.
- August 2025: 16% Strong Buy, 57% Buy, 6% Hold.
- Notable increase in Hold ratings from 6% to 10% in the last quarter.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-23 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-10-22 | Buy | Buy | TD Cowen |
| 2025-10-22 | Overweight | Overweight | Barclays |
| 2025-10-08 | Neutral | Buy | Rothschild & Co |
| 2025-10-07 | Outperform | Outperform | Evercore ISI Group |
Analyst Recommendations with Change of Opinion
Recent changes in analyst recommendations highlight evolving opinions. Rothschild & Co shifted to Neutral from Buy, indicating tempered expectations. Contrarily, upgrades by Scotiabank and Barclays reflect renewed optimism in DHR's prospects. These shifts suggest varying levels of confidence and risk perception among analysts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-08 | Neutral | Buy | Rothschild & Co |
| 2025-07-11 | Sector Outperform | Sector Perform | Scotiabank |
| 2025-04-10 | Overweight | Equal Weight | Barclays |
| 2025-03-14 | Buy | Hold | Stifel |
| 2025-02-03 | Market Perform | Outperform | Raymond James |
Interpretation
The market sentiment regarding Danaher Corporation remains cautiously optimistic, with a predominant Buy stance among analysts. The increase in Hold ratings suggests a balanced view of potential risks and rewards. Recent downgrades and upgrades indicate a mixed perception of upcoming performance, with some analysts viewing current market conditions as a signal to moderate expectations. The company's proven ability to innovate across segments provides a stable foundation, though varying analyst confidence reflects market sensitivity to macroeconomic conditions.
Conclusion
In conclusion, Danaher Corporation exudes a steady yet cautious optimism from analysts. The increase in Hold recommendations suggests a more reserved outlook, but the strong percentage of Buy ratings reveals substantial confidence in the company's long-term growth potential. With shifts in recommendation categories, analysts appear to be navigating uncertain market environments with a balanced approach. As such, potential investors should weigh both the strong fundamentals and the potential risks highlighted by varying analyst perspectives.